Targeting Taspase1 for Cancer Therapy—Response
Abstract
Targeting Taspase1 for Cancer Therapy—Response var callbackToken='5058BFADFEAB7CA'; Skip to main page content Home OnlineFirst Current Issue Past Issues Subscriptions Alerts Feedback AACR Publications AACR Home Search GO Advanced Search Institution: DeepDyve User Name Password Sign In Targeting Taspase1 for Cancer Therapy—Response David Y. Chen 1 , Shugaku Takeda 2 , Toshinao Oyama 2 , and James J. Hsieh 2 Authors' Affiliations: 1 Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; and 2 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York Corresponding Author: James J. Hsieh, Memorial Sloan-Kettering Cancer Center, 415 E. 68 th Street, Z801, New York, NY10065. Phone: 646-888-3263; Fax: 646-888-3266; E-mail: hsiehj@mskcc.org We appreciate the interests of Stauber and colleagues in our study, identifying a small-molecule Taspase1 inhibitor (TASPIN) NSC48300 that disrupts cancer cell growth ( 1 ). First, regarding the expression level of Taspase1 in 293T cells, Taspase1 was first purified from 293T cells on the basis of the presence of potent proteolytic activity ( 2 ). Therefore, the claim that 293T has no measurable expression of Taspase1 is incorrect. The activity of Taspase1 in 293T cells is quite evident as the dual fluorescent proteolytic reporter (GFP 2XNES-MLL(2500-2900)-3XNLS dsRED2)